EGFR Signaling and Drug Discovery

Publisher： Karger

E-ISSN： 1423-0232|77|6|400-410

ISSN： 0030-2414

Source： Oncology, Vol.77, Iss.6, 2010-02, pp. : 400-410

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Map of Alzheimer's Disease–Signaling Pathways: A Hope for Drug Target Discovery

By  

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 93, Iss. 5, 2013-05 ,pp. : 399-401

John Wiley & Sons Inc

Access to resources Recommend Favorite

Metabolomics in Drug Discovery and Development

By  

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 94, Iss. 5, 2013-11 ,pp. : 559-561

John Wiley & Sons Inc

Access to resources Recommend Favorite

Drug Discovery and Development

By  

BASIC AND CLINICAL PHARMACOLOGY & TOXICOLOGY (ELECTRONIC), Vol. 115, Iss. s1, 2014-07 ,pp. : 92-161

John Wiley & Sons Inc

Access to resources Recommend Favorite

Pathology in drug discovery and development

By  

THE JOURNAL OF PATHOLOGY, Vol. 232, Iss. 2, 2014-01 ,pp. : 99-102

John Wiley & Sons Inc

Access to resources Recommend Favorite

Integrated effect of EGFR and PAR-1 signaling crosstalk on airway hyperresponsiveness

By    

International Journal of Molecular Medicine, Vol. 30, Iss. 1, 2012-01 ,pp. : 41-48

Spandidos Publications

Access to resources Recommend Favorite